Stroke and cardiovascular diseases: The need for a global approach for prevention and drug development

International Journal of Stroke

Volumn 2, Issue 2, 2007, Pages 104-108

  Hilbrich, Lutz ^a   Truelsen, Thomas ^b   Yusuf, Salim ^c  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b HILLERØD HOSPITAL   (Denmark)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Cardiovascular; Clinical trials; Global; Health care; High income countries; Low income countries; Stroke

Indexed keywords

FIBRINOLYTIC AGENT; RAMIPRIL; TELMISARTAN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; EPIDEMIC; FIBRINOLYTIC THERAPY; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; INTERNATIONAL COOPERATION; LOWEST INCOME GROUP; MONOTHERAPY; MORTALITY; PATENT; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RESEARCH ETHICS; REVIEW; RISK FACTOR; STRATEGIC PLANNING; STROKE;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; INTERNATIONAL COOPERATION; STROKE; WORLD HEALTH;

EID: 34247880446     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2007.00118.x     Document Type: Review

References (46)

1. Reddy KS, Yusuf S: Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596-601.
2. IMS Global Insights: http://www.imshealth.com/web/content/ 0,3148,64576068_63872702_70260998_73052844,00.html (Accessed October 19, 2006).
3. World Health Organization: http://www.who.int/countries/en/ (Accessed Oct 19, 2006).
4. Sacco RL, Adams R, Albers G et al. American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617.
5. Gaziano TA: Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112: 3547-53.
6. Padmavati S: Prevention of heart disease in India in the 21st century: need for a concerted effort. Indian Heart J 2002; 54: 99-102.
7. Mackay J, Mensah G: The atlas of heart disease and stroke. World Health Organization. http://www.who.int/cardiovascular_diseases/resources/ atlas/en/ (Accessed May 25, 2006).
8. Ezzati M, Vander Hoorn S, Lawes CM et al. Rethinking the 'diseases of affluence' paradigm: Global patterns of nutritional risks in relation to economic development. PLoS Med 2005; 2: E133.
9. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, MA, USA: Harvard School of Public Health, 1996.
10. Asplund K: What MONICA told us about stroke. Lancet Neurol 2005; 4: 64-8.
11. Dominguez LJ, Galioto A, Ferlisi A et al. Ageing, lifestyle modifications, and cardiovascular disease in developing countries. J Nutr Health Aging 2006; 10: 143-9.
12. Critchley J, Liu J, Zhao D, Wei W, Capewell S: Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004; 110: 1236-44.
13. The Center for Global Health and Economic Development: A race against time. The challenge of cardiovascular disease in developing countries. 2004. http://www.oxha.org/about/media-resources/ note-on-a-race-against-time (Accessed May 25, 2006).
14. Truelsen T, BonitaAR, Jamrozik K: Surveillance of stroke: a global perspective. Int J Epidemiol 2001; 30: 11-6.
15. Yach D, Hawkes C, Gould CL, Hofman KJ: The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA 2004; 291: 2616-22.
16. Caro JJ, Huybrechts KF, Duchesne I: Management patterns and costs of acute ischemic stroke: An international study. For the Stroke Economic Analysis Group. Stroke 2000; 31: 582-90.
17. Abegunde D, Stanciole A: World Health Organization Working Paper: An estimation of the economic impact of chronic noncommunicable diseases in selected countries. 2006. http://www.who.int/chp/chronic_disease_report/en/ (Accessed September 8, 2006).
18. Khor GL: Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001; 10: 76-80.
19. Zhang KL, Liu M, Li D: Health care delivery system and major health issues in China. Med J Aust 1996; 165: 638-40.
20. Blumenthal D, Hsiao W: Privatization and its discontents - the evolving Chinese health care system. New Engl J Med 2005; 353: 1165-70.
21. Whitehead M, Dahlgren G, EvaCs T: Equity and health sector reforms: can low-income countries escape the medical poverty trap? Lancet 2001; 358: 833-6.
22. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ: Household catastrophic health expenditure: A multicountry analysis. Lancet 2003; 362: 111-7.
23. Commission on Macroeconomics and Health: Macroeconomics and health: investing health for economic development. World Health Organization, 2001. http://www.eldis.org/static/DOC6008.htm (Accessed May 25, 2006).
24. Vorster HH: The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr 2002; 5: 239-43.
25. Ringleb PA, Schwark C, Schwninger M, Schellinger PD: Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke. Expert Opin Pharmacother 2005; 6: 359-67.
26. Szucs TD, Bramkamp M: Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: A review. J Thromb Haemost 2006; 4: 1180-5.
27. Dubinsky R, Lai SM: Mortality of stroke patients treated with thrombolysis: Analysis of nationwide inpatient sample. Neurology 2006; 66: 1742-4.
28. Kapp C: Sparks fly over patents and vital drugs at world health assembly. Lancet 2003; 361: 1873.
29. Centre for Medicines Research (CMR) International. 2004. Global Clinical Performance Metrics Programme Report. Industry Report, July 2004.
30. Mills EJ, Nachega JB, Buchan I et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 2006; 296: 679-90.
31. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-52.
32. Lopez AD, Murray CCJL: The global burden of disease, 1990-2020. Nature Medicine 1998; 4: 1241-3.
33. Lavados PM, Sacks C, Prina L et al. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: A 2-year community-based prospective study (PISCIS Project). Lancet 2005; 365: 2206-15.
34. Smadja D, Cabre P, May F et al. ERMANCIA: Epidemiology of stroke in MaMtinique, French West Indies: Part I: methodology, incidence, and 30-day case fatality rate. Stroke 2001; 32: 2741-7.
35. Erdine S, Aran SN: Current status of hypertension control around the world. Clin Exp Hypertens 2004; 26: 731-8.
36. Lemogoum D, Degaute J-P, Bovet P: Stroke prevention, treatment, and rehabilitation in sub-Saharan Africa. Am J Prev Med 2005; 29: 95-101.
37. Lawes CM, Vander HS, Law MR, Elliott P, MacMahon S, Rodgers A: Blood pressure and the global burden of disease 2000. Part 1: Estimates of blood pressure levels. J Hypertens 2006; 24: 413-22.
38. Lawes CM, Vander HS, Law MR, Elliott P, MacMahon S, Rodgers A: Blood pressure and the global burden of disease 2000. Part II: Estimates of attributable burden. J Hypertens 2006; 24: 423-30.
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/cache/ compo/276-254-1.html (Accessed May 25, 2006).
40. World Medical Association Declaration of Helsinki. http://www.wma.net/e/ policy/b3.htm (Accessed May 25, 2006).
41. Jenkins RA, Chinaworapong S, Morgan PA et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 171-7.
42. Kasper CK: Conduct of clinical trials in developing countries. Haemophilia 2002; 8: 166-9.
43. Mendis S, Abegunde D, Yusuf S et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Heath Organ 2005; 83: 820-9.
44. Dunbabin D: Cost-effective intervention in stroke. Pharmecoeconomics 1992; 2: 468-99.
45. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F: The global stroke initiative. Lancet Neurol 2004; 3: 391-3.
46. WHO-Health statistics and health information systems. http://www.who.int/ healthinfo/statistics/bodprojections2030/en/index.html (Accessed October 20, 2006).